Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
On Thursday, Stifel analysts increased their price target for Elanco Animal Health (NYSE:ELAN) shares to $15.00, up from the previous $13.00, while reiterating a Buy rating on the stock. The adjustment follows Elanco’s strong quarterly performance and the company’s forward-looking 2025 guidance, which resulted in a significant 25% rise in the stock price. This surge is reflected in InvestingPro data showing a remarkable 26.82% return over the past week. The analysts noted that despite the recent appreciation, Elanco’s stock is only trading slightly above its Pre-Liberation Day levels at $12.20, suggesting the market has not fully recognized the company’s improved business position. According to InvestingPro’s Fair Value analysis, the stock appears slightly undervalued, though the RSI suggests it’s currently in overbought territory.
Elanco’s product Credelio Quattro (CQ) is reportedly gaining momentum in the companion animal (CA) market, which is one of the largest and fastest-growing segments. The analysts believe CQ has a promising future as it is the third product to enter this competitive market. Additionally, Zenrelia is performing well internationally, with European Union approval expected in the near future and potential improvements to the U.S. product label on the horizon. The company’s strong market position is reflected in its healthy gross profit margin of 54.88% and overall GOOD financial health score, according to InvestingPro analysis.
The Farm Animal division is also showing positive signs, with Experior gaining traction and Bovaer being highlighted as a longer-term opportunity. Stifel’s analysts maintain their thesis that Elanco is poised for substantial growth. They predict that by 2026 and beyond, Elanco’s EBITDA growth, expected to be in the high single digits, will surpass revenue growth, projected in the mid-single digits. Furthermore, they anticipate that earnings per share (EPS) growth, expected to be in the low double digits, will outpace EBITDA growth due to the company’s debt reduction efforts.
The report concludes with a perspective on Elanco’s valuation, suggesting that the current stock price does not yet reflect the company’s growth potential as outlined by the analysts’ growth algorithm.
In other recent news, Elanco Animal Health reported better-than-expected financial results for the first quarter of 2025. The company achieved adjusted earnings per share of $0.37, surpassing the forecasted $0.31, while revenue reached $1.19 billion, exceeding the anticipated $1.17 billion. Elanco has also raised its full-year revenue guidance, citing favorable currency exchange rates as a contributing factor. The company continues to focus on innovation and product launches, with successful introductions like Credelio Quattro and ZENRELIA playing a significant role in driving growth. Despite a slight year-over-year decrease in reported revenue, Elanco’s diverse portfolio helped maintain its competitive position. Analysts have taken note of Elanco’s strategic execution, with firms like Stifel inquiring about the company’s approach to mitigating potential tariff impacts. The company remains confident in its growth trajectory, supported by robust performance in its innovation portfolio and strategic interventions to address external challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.